Biomarker screening for allergic rhinitis treatment evaluation using a microneedle patch

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a new transdermal immunotherapy method for patients with allergic rhinitis caused by house dust mites. It involves collecting clinical indicators and samples from participants before and after treatment to monitor immune responses. The goal is to improve treatment satisfaction and reduce the risks associated with traditional immunotherapy methods, such as injections and sublingual tablets. Participants will include both patients with allergic rhinitis and healthy controls to compare responses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* A. patient group of House dust mite

  1. Adult male and female patients aged 19 to 60 with allergic rhinitis caused by the antigen of the American house dust mite (It is judged that the positive for the house dust mite is MAST ≥ Class 3 or ImmunoCAP® ≥3.5 kUA/L)
  2. Moderate-severe persistent rhinitis when evaluated according to ARIA (Allergic rhinitis and its impact on asthma)
  3. A person who has signed a written consent to participate in this clinical trial at his/her own discretion after fully explaining the purpose, contents, characteristics of the test drug, and expected adverse reactions prior to participation in the clinical trial B. Control group (Normal person)

  <!-- -->

  1. Adults 19 years of age or older who are judged to be free from skin diseases or allergic diseases through medical examination and visual observation by a specialist
  2. A person who agrees to provide samples derived from the human body
  3. A person who voluntarily agreed to this study and prepared a consent form after approval of the IRB

Exclusion Criteria:

* A. patient group of House dust mite

  1. Patients who are taking drugs that may affect efficacy evaluation (but can participate if there is no change in the drug taken during the study period)
  2. Within six months of participation in the study, other clinical trial drugs or biological equivalence test drugs, biological agents (e.g. Anti-IgE) were administered
  3. If there is a skin disease or tattoo in the area where the medication is applied
  4. Immunosuppressive therapy or systemic steroid therapy for acute and chronic inflammatory skin diseases
  5. A person in charge of testing or a person in charge of testing deemed inappropriate to participate in the test due to other reasons B. Control (Normal person)

  <!-- -->

  1. Patients with allergic diseases such as atopic dermatitis or allergic asthma and rhinitis
  2. A person who voluntarily disagrees with this study after approval of the IRB and has not completed the consent form

Where it's running

• Yonsei University Health System, Severance Hospital
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Kyung Hee Park — Yonsei University Health System, Severance Hospital
• Study coordinator: Kyung Hee Park
• Email: white182@yuhs.ac
• Phone: +82-2-2228-1947

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PollenVax for mugwort pollen allergy

  This Phase 2 study tests PollenVax, a quick-course subcutaneous immunotherapy, in adults with mugwort pollen–triggered allergic rhinitis.

  Recruiting Phase 2 Kazakh National Agrarian University · Almaty, Almaty · NCT07563439

• Evaluating air purifiers for improving allergic rhinitis symptoms

  This study is testing whether using a special air purifier can help adults with moderate to severe allergies feel better compared to using a fake air purifier.

  Recruiting Yonsei University · Seoul · NCT06890572

• Assessing the impact of airway allergic diseases on children's and parents' quality of life

  This study looks at how having asthma or allergies affects the quality of life for children and their parents, comparing those getting special treatment to those on regular care.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT06535087

• Using ganciclovir capsules to treat severe allergic rhinitis

  This study is testing if ganciclovir capsules can help people with severe allergic rhinitis feel better and improve their quality of life.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06436534

• Exploring the effects of ZhenQiFuZheng granules on allergic rhinitis

  This study is testing if ZhenQi FuZheng granules can help people with allergic rhinitis by looking at how they affect gut bacteria and inflammation.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06427577

• Evaluating a new treatment for allergies to certain trees and grasses

  This study is testing a new allergy treatment for people aged 12 to 65 who are sensitive to certain tree and grass pollens to see if it can help reduce their allergy symptoms.

  Recruiting at 9 sites Phase 3 Inmunotek S.L. · Valladolid, Castille and León and 26 other locations · NCT04898283

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.